Ceribell Launches First FDA-Cleared Delirium Monitor With $2,171 CMS Add-On Payment
CBLL has more than doubled off its 52-week low of $10.85.
Summary
Ceribell began selling its delirium monitoring module on the existing Ceribell EEG headband, making it the first and only FDA-cleared device to aid delirium screening and monitoring. The clearance came in December 2025; this is the revenue-generating step, following a multi-hospital pilot. CMS granted a New Technology Add-on Payment of up to $2,171 per eligible Medicare case effective October 1, 2026, which removes a real adoption hurdle for hospitals weighing the cost. The pitch is large: delirium hits roughly 30% of ICU patients and up to 80% of those on ventilators, and the same hardware already sits in accounts using seizure detection. This lands after a strong Q2 ($28.1M revenue, up 33% year-over-year, guidance raised to $114M-$117M), so the launch is the next leg of that growth story rather than a rescue.
At the time of this announcement, CBLL was trading at $26.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $10.85 to $28.19. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.